Inhibition of cathepsin S reduces allogeneic T cell priming but not graft-versus-host disease against minor histocompatibility antigens

Biology of Blood and Marrow Transplantation

Volumn 18, Issue 4, 2012, Pages 546-556

  Fujii, Hisaki ^a   Ivison, Sabine M ^b   Shimizu, Hiromi ^c   Kajiwara, Ryosuke ^d   Kariminia, Amina ^b   Yan, Matthew ^b   Dutz, Jan P ^b   Schultz, Kirk R ^b  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c StemCell Technologies Inc   (Canada)

^d YOKOHAMA CITY UNIVERSITY HOSPITAL   (Japan)

Author keywords

Antigen presentation; Cathepsin; Chloroquine; Graft versus host disease; T cell priming

Indexed keywords

CATHEPSIN B; CATHEPSIN L; CATHEPSIN S; CATHEPSIN S INHIBITOR; GAMMA INTERFERON; INTERLEUKIN 6; MINOR HISTOCOMPATIBILITY ANTIGEN; MORPHOLINUREA LEUCINE HOMOPHENYLALANINE VINYLSULFONE PHENYL; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN PRESENTATION; ANTIGEN RECOGNITION; ARTICLE; CD4+ T LYMPHOCYTE; CELL PROLIFERATION; COMPETITIVE INHIBITION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE SEVERITY; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; GENETIC VARIABILITY; GRAFT VERSUS HOST REACTION; IN VITRO STUDY; IN VIVO STUDY; LYMPH NODE CELL; MACROPHAGE; MINOR HISTOCOMPATIBILITY COMPLEX; MOUSE; NONHUMAN; PROTEIN EXPRESSION; SPLEEN CELL; T LYMPHOCYTE;

ANIMALS; ANTIGEN PRESENTATION; BONE MARROW TRANSPLANTATION; CATHEPSINS; CD4-POSITIVE T-LYMPHOCYTES; DIPEPTIDES; ENZYME INHIBITORS; FEMALE; GRAFT VS HOST DISEASE; HISTOCOMPATIBILITY ANTIGENS CLASS II; INJECTIONS, INTRAPERITONEAL; MAJOR HISTOCOMPATIBILITY COMPLEX; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MINOR HISTOCOMPATIBILITY ANTIGENS; SPLEEN; SULFONES; TRANSPLANTATION, HOMOLOGOUS;

EID: 84858079744     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2011.11.027     Document Type: Article

References (54)

1. Schultz K.R., Bader S., Paquet J., Li W. Chloroquine treatment affects T-cell priming to minor histocompatibility antigens and graft-versus-host disease. Blood 1995, 86:4344-4352.
2. Schultz K.R., Su W.N., Hsiao C.C., et al. Chloroquine prevention of murine MHC-disparate acute graft-versus-host disease correlates with inhibition of splenic response to CpG oligodeoxynucleotides and alterations in T-cell cytokine production. Biol Blood Marrow Transplant 2002, 8:648-655.
3. Fox R.I. Mechanism of action of hydroxychloroquine as an antirheumatic drug. Semin Arthritis Rheum 1993, 23:82-91.
4. Ziegler H.K., Unanue E.R. Decrease in macrophage antigen catabolism caused by ammonia and chloroquine is associated with inhibition of antigen presentation to T cells. Proc Natl Acad Sci USA 1982, 79:175-178.
5. She K., Gilman A.L., Aslanian S., et al. Altered toll-like receptor 9 responses in circulating B cells at the onset of extensive chronic graft-versus-host disease. Biol Blood Marrow Transplant 2007, 13:386-397.
6. Fong T., Trinkaus K., Adkins D., et al. A randomized double-blind trial of hydroxychloroquine for the prevention of chronic graft-versus-host disease after allogeneic peripheral blood stem cell transplantation. Biol Blood Marrow Transplant 2007, 13:1201-1206.
7. Gilman AL, Schultz KR, Goldman FD, et al. Randomized trial of hydroxychloroquine for newly diagnosed chronic graft-versus-host disease in children: a Children's Oncology Group Study. Biol Blood Marrow Transplant.
8. Nakagawa T.Y., Brissette W.H., Lira P.D., et al. Impaired invariant chain degradation and antigen presentation and diminished collagen-induced arthritis in cathepsin S null mice. Immunity 1999, 10:207-217.
9. Villadangos J.A., Riese R.J., Peters C., Chapman H.A., Ploegh H.L. Degradation of mouse invariant chain: roles of cathepsins S and D and the influence of major histocompatibility complex polymorphism. J Exp Med 1997, 186:549-560.
10. Shi G.P., Villadangos J.A., Dranoff G., et al. Cathepsin S required for normal MHC class II peptide loading and germinal center development. Immunity 1999, 10:197-206.
11. Beers C., Burich A., Kleijmeer M.J., Griffith J.M., Wong P., Rudensky A.Y. Cathepsin S controls MHC class II-mediated antigen presentation by epithelial cells in vivo. J Immunol 2005, 174:1205-1212.
12. Bania J., Gatti E., Lelouard H., et al. Human cathepsin S, but not cathepsin L, degrades efficiently MHC class II-associated invariant chain in nonprofessional APCs. Proc Natl Acad Sci USA 2003, 100:6664-6669.
13. Gilman A.L., Chan K.W., Mogul A., et al. Hydroxychloroquine for the treatment of chronic graft-versus-host disease. Biol Blood Marrow Transplant 2000, 6:327-334.
14. Riese R.J., Wolf P.R., Bromme D., et al. Essential role for cathepsin S in MHC class II-associated invariant chain processing and peptide loading. Immunity 1996, 4:357-366.
15. Palmer J.T., Rasnick D., Klaus J.L., Bromme D. Vinyl sulfones as mechanism-based cysteine protease inhibitors. J Med Chem 1995, 38:3193-3196.
16. Larson E.T., Parussini F., Huynh M.H., et al. Toxoplasma gondii cathepsin L is the primary target of the invasion-inhibitory compound morpholinurea-leucyl-homophenyl-vinyl sulfone phenyl. J Biol Chem 2009, 284:26839-26850.
17. Riese R.J., Mitchell R.N., Villadangos J.A., et al. Cathepsin S activity regulates antigen presentation and immunity. J Clin Invest 1998, 101:2351-2363.
18. Saegusa K., Ishimaru N., Yanagi K., et al. Cathepsin S inhibitor prevents autoantigen presentation and autoimmunity. J Clin Invest 2002, 110:361-369.
19. Barnden M.J., Allison J., Heath W.R., Carbone F.R. Defective TCR expression in transgenic mice constructed using cDNA-based alpha- and beta-chain genes under the control of heterologous regulatory elements. Immunol Cell Biol 1998, 76:34-40.
20. Cooke K.R., Kobzik L., Martin T.R., et al. An experimental model of idiopathic pneumonia syndrome after bone marrow transplantation: I. The roles of minor H antigens and endotoxin. Blood 1996, 88:3230-3239.
21. Anderson B.E., McNiff J.M., Matte C., Athanasiadis I., Shlomchik W.D., Shlomchik M.J. Recipient CD4+ T cells that survive irradiation regulate chronic graft-versus-host disease. Blood 2004, 104:1565-1573.
22. Fiebiger E., Meraner P., Weber E., et al. Cytokines regulate proteolysis in major histocompatibility complex class II-dependent antigen presentation by dendritic cells. J Exp Med 2001, 193:881-892.
23. Beers C., Honey K., Fink S., Forbush K., Rudensky A. Differential regulation of cathepsin S and cathepsin L in interferon gamma-treated macrophages. J Exp Med 2003, 197:169-179.
24. Kitamura H., Kamon H., Sawa S., et al. IL-6-STAT3 controls intracellular MHC class II alphabeta dimer level through cathepsin S activity in dendritic cells. Immunity 2005, 23:491-502.
25. Wettstein P.J., Colombo M.P. Immunodominance in the T cell response to multiple non-H-2 histocompatibility antigens. IV. Partial tissue distribution and mapping of immunodominant antigens. J Immunol 1987, 139:2166-2171.
26. Korngold R., Wettstein P.J. Immunodominance in the graft-vs-host disease T cell response to minor histocompatibility antigens. J Immunol 1990, 145:4079-4088.
27. Zhang Y., Joe G., Hexner E., Zhu J., Emerson S.G. Alloreactive memory T cells are responsible for the persistence of graft-versus-host disease. J Immunol 2005, 174:3051-3058.
28. de Witte M.A., Toebes M., Song J.Y., Wolkers M.C., Schumacher T.N. Effective graft depletion of MiHAg T-cell specificities and consequences for graft-versus-host disease. Blood 2007, 109:3830-3838.
29. Kappel B.J., Pinilla-Ibarz J., Kochman A.A., et al. Remodeling specific immunity by use of MHC tetramers: demonstration in a graft-versus-host disease model. Blood 2006, 107:2045-2051.
30. Choi E.Y., Christianson G.J., Yoshimura Y., et al. Real-time T-cell profiling identifies H60 as a major minor histocompatibility antigen in murine graft-versus-host disease. Blood 2002, 100:4259-4265.
31. Friedman T.M., Gilbert M., Briggs C., Korngold R. Repertoire analysis of CD8+ T cell responses to minor histocompatibility antigens involved in graft-versus-host disease. J Immunol 1998, 161:41-48.
32. Hamilton B.L. L3T4-positive T cells participate in the induction of graft-vs-host disease in response to minor histocompatibility antigens. J Immunol 1987, 139:2511-2515.
33. Korngold R., Sprent J. Variable capacity of L3T4+ T cells to cause lethal graft-versus-host disease across minor histocompatibility barriers in mice. J Exp Med 1987, 165:1552-1564.
34. Anderson B.E., McNiff J., Yan J., et al. Memory CD4+ T cells do not induce graft-versus-host disease. J Clin Invest 2003, 112:101-108.
35. Zhang T., Maekawa Y., Sakai T., et al. Splenic cathepsin L is maturated from the proform by interferon-gamma after immunization with exogenous antigens. Biochem Biophys Res Commun 2001, 283:499-506.
36. Burster T., Giffon T., Dahl M.E., et al. Influenza A virus elevates active cathepsin B in primary murine DC. Int Immunol 2007, 19:645-655.
37. Korngold R., Sprent J. Lethal graft-versus-host disease after bone marrow transplantation across minor histocompatibility barriers in mice. Prevention by removing mature T cells from marrow. J Exp Med 1978, 148:1687-1698.
38. Shlomchik W.D. Graft-versus-host disease. Nat Rev Immunol 2007, 7:340-352.
39. Giver C.R., Li J.M., Hossain M.S., Lonial S., Waller E.K. Reconstructing immunity after allogeneic transplantation. Immunol Res 2004, 29:269-282.
40. Foster A.E., Marangolo M., Sartor M.M., et al. Human CD62L- memory T cells are less responsive to alloantigen stimulation than CD62L+ naive T cells: potential for adoptive immunotherapy and allodepletion. Blood 2004, 104:2403-2409.
41. Chen B.J., Cui X., Sempowski G.D., Liu C., Chao N.J. Transfer of allogeneic CD62L- memory T cells without graft-versus-host disease. Blood 2004, 103:1534-1541.
42. Berger M., Wettstein P.J., Korngold R. T cell subsets involved in lethal graft-versus-host disease directed to immunodominant minor histocompatibility antigens. Transplantation 1994, 57:1095-1102.
43. Schlegel P.G., Aharoni R., Smilek D.E., et al. Prevention of graft-versus-host disease by peptides binding to class II major histocompatibility complex molecules. Blood 1994, 84:2802-2810.
44. Salmeron G., Lipsky P.E. Immunosuppressive potential of antimalarials. Am J Med 1983, 75:19-24.
45. Ertel W., Morrison M.H., Ayala A., Chaudry I.H. Chloroquine attenuates hemorrhagic shock-induced suppression of Kupffer cell antigen presentation and major histocompatibility complex class II antigen expression through blockade of tumor necrosis factor and prostaglandin release. Blood 1991, 78:1781-1788.
46. Karres I., Kremer J.P., Dietl I., Steckholzer U., Jochum M., Ertel W. Chloroquine inhibits proinflammatory cytokine release into human whole blood. Am J Physiol 1998, 274:R1058-R1064.
47. Macfarlane D.E., Manzel L. Antagonism of immunostimulatory CpG-oligodeoxynucleotides by quinacrine, chloroquine, and structurally related compounds. J Immunol 1998, 160:1122-1131.
48. Yi A.K., Krieg A.M. Rapid induction of mitogen-activated protein kinases by immune stimulatory CpG DNA. J Immunol 1998, 161:4493-4497.
49. Jones S.C., Murphy G.F., Friedman T.M., Korngold R. Importance of minor histocompatibility antigen expression by nonhematopoietic tissues in a CD4+ T cell-mediated graft-versus-host disease model. J Clin Invest 2003, 112:1880-1886.
50. Wettstein P.J. Immunodominance in the T-cell response to multiple non-H-2 histocompatibility antigens. II. Observation of a hierarchy among dominant antigens. Immunogenetics 1986, 24:24-31.
51. Lu Y., Waller E.K. Dichotomous role of interferon-gamma in allogeneic bone marrow transplant. Biol Blood Marrow Transplant 2009, 15:1347-1353.
52. Rozmus J, Schultz KR, Wynne K, et al. Early and late extensive chronic graft-versus-host disease in children is characterized by different Th1/Th2 cytokine profiles: findings of the Children's Oncology Group Study ASCT0031. Biol Blood and Marrow TRansplantation 2011, 17:1804-1813.
53. Belizaire R., Unanue E.R. Targeting proteins to distinct subcellular compartments reveals unique requirements for MHC class I and II presentation. Proc Natl Acad Sci USA 2009, 106:17463-17468.
54. Lee-Dutra A, Wiener DK, Sun S Cathepsin S inhibitors: 2004-2010. Expert Opin Ther Pat 2011, 21:311-337.